Core Viewpoint - Haemonetics Corporation has announced the acquisition of Vivasure Medical Limited, enhancing its portfolio in the vessel closure market with innovative technology aimed at improving patient outcomes [1][4]. Acquisition Details - The acquisition involves an upfront cash payment of €100 million, approximately €52 million net after accounting for previous investments and loans, with potential additional contingent consideration of up to €85 million based on sales growth and milestone achievements [3]. - The transaction was financed through Haemonetics' available cash on hand [3]. Product Information - Vivasure's PerQseal Elite system utilizes a bioabsorbable patch for sealing large-bore arteriotomies and venotomies, providing a sutureless and fully absorbable solution for various medical procedures [2]. - The system has received CE Mark approval in Europe and a Premarket Approval application was submitted to the U.S. FDA in 2025 [2]. Strategic Implications - The acquisition is expected to expand Haemonetics' range of closure devices and strengthen its position in the growing structural heart and endovascular procedure markets [4]. - The clinical performance of the PerQseal Elite system, demonstrated by a 0% major complication rate at thirty-day follow-up, positions Haemonetics for increased leadership in advanced closure technologies [2][4]. Company Background - Haemonetics is a global medical technology company focused on improving healthcare quality and efficiency through innovative solutions [5]. - Vivasure Medical Limited specializes in advanced polymer implants and delivery systems for minimally invasive vessel closure [6].

Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].